Wearable Injectors Market - Global Forecast To 2030
商品番号 : SMB-4379
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 452 |
| 図表数 | 549 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、ウェアラブルインジェクター市場を、製品、技術、用途、投与方法、治療用途、製造タイプ、エンドユーザー、地域の観点から分析しています。また、市場の成長に影響を与える要因（成長促進要因、阻害要因、機会、課題）についても分析しています。市場の機会と課題を分析し、市場リーダー企業の競争環境の詳細を提供します。さらに、マイクロマーケットを個々の成長傾向の観点から分析し、5つの主要地域とそれぞれの国における市場セグメントの収益予測も示しています。
本レポートは、既存企業だけでなく、新興企業や小規模企業も市場動向を把握し、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入した企業は、以下に示す5つの戦略のうち1つ以上を活用できます。
ウェアラブルインジェクター市場は、2025年の113億3,000万米ドルから2030年には189億1,000万米ドルに成長し、予測期間中に年平均成長率（CAGR）10.8%で成長すると予測されています。糖尿病、がん、心血管疾患などの慢性疾患の罹患率の上昇により、薬物療法の正確で制御された継続的な投与に対する需要が生まれ、ウェアラブルインジェクター技術の成長を大きく促進しています。さらに、デバイスエンジニアリングの進歩、研究開発費の増加、モノのインターネット（IoT）と遠隔モニタリングの統合により、患者の安全性が高まり、薬剤投与の効率が向上しています。さらに、従来の入院環境ではなく、在宅ヘルスケアソリューションへの移行により、これらの高度な投与システムに対する需要がさらに高まっています。さらに、ウェアラブルインジェクターを取り巻く厳格な規制の枠組みにより、より安全で信頼性の高いシステムの開発が促進され、市場拡大が後押しされています。
The wearable injectors market is projected to grow from USD 11.33 billion in 2025 to USD 18.91 billion by 2030, at a CAGR of 10.8% during the forecast period. The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has created a demand for the precise, controlled, and continuous delivery of pharmacological therapies, significantly driving the growth of wearable injector technologies. Moreover, advancements in device engineering, increased spending on research and development, and the integration of the Internet of Things (IoT) and remote monitoring are enhancing patient safety and improving the efficiency of drug administration. Additionally, the shift towards home-based healthcare solutions, as opposed to traditional inpatient settings, is generating further demand for these advanced delivery systems. Furthermore, stringent regulatory frameworks surrounding wearable injectors are promoting the development of safer and more reliable systems, thereby reinforcing market expansion.
“The spring-based technology segment accounted for the largest share of the wearable injectors market, by technology, in 2024.”
By technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. Spring-based wearable injectors currently hold the largest share of the market because of their simple design, cost-effectiveness, and reliability. These devices utilize a mechanical spring mechanism to deliver drugs subcutaneously, which eliminates the need for complex motors or batteries. Their ease of manufacturing and reduced risk of mechanical failure make them a preferred choice for both manufacturers and patients. Furthermore, spring-based injectors are widely used in the management of chronic diseases, particularly in oncology and diabetes, where frequent and controlled dosing is crucial. The widespread adoption of these injectors in both developed and developing markets is expected to sustain their dominance through 2030.
“The disposable wearable injectors segment is expected to dominate the market, by usage, during the forecast period.”
The wearable injectors market is divided into two categories based on usage: disposable and reusable injectors. The disposable wearable injectors segment is expected to dominate the usage category during the forecast period. These devices are designed for single use, which helps reduce the risk of contamination, improve safety, and enhance patient convenience. They are especially favored in situations that require strict sterility, such as oncology treatments and the administration of biologic drugs. Additionally, the growing prevalence of biologics and personalized therapies, which often necessitate self-administration, has increased the demand for user-friendly, ready-to-use injectors. The absence of the need for maintenance, calibration, or cleaning further makes disposable injectors appealing to both patients and healthcare providers, solidifying their position as market leaders.
“The North American region is expected to capture the largest share during the forecast period.”
North America continues to be the dominant and fastest-growing region in the wearable injectors market. This growth is primarily driven by a robust healthcare infrastructure, high healthcare expenditures, and the early adoption of advanced drug delivery technologies. The US and Canada lead the way, with a significant portion of the population suffering from chronic diseases such as diabetes, cancer, and autoimmune disorders—conditions that require regular and precise medication administration. The region also benefits from a strong presence of key market players and continuous innovation in biologics and personalized medicine, both of which demand sophisticated delivery solutions like wearable injectors. Additionally, the increasing trend toward outpatient care and home-based treatment, along with favorable reimbursement policies and strong regulatory support, further accelerates market growth. Technological advancements, including the integration of digital health features and connectivity in wearable injectors, are improving treatment adherence, patient monitoring, and clinical outcomes. These developments align well with North America’s focus on value-based care, further solidifying the region’s leadership in the global wearable injectors market.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Breakdown of demand-side primary interviews:
- By Company Type: Hospitals (45%), Home Care Settings (30%), Ambulatory Surgery Centers/Specialty Infusion Centers (20%), and Other End Users (5%)
- By Designation: Healthcare Professionals (35%), Department Heads (27%), Procurement Heads (22%), and Other Designations (16%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Research Coverage
This report studies the wearable injectors market based on product, technology, usage, delivery method, therapeutic application, manufacturing type, end user, and region. It also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the market’s opportunities and challenges and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established companies and new or smaller firms understand market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.
This report provides insights into the following points:
- Analysis of key drivers (increased shift to home care settings, rising prevalence of chronic diseases, and rising aging population), restraints (high cost of wearable injectors), opportunities (high growth potential in emerging economies), and challenges (lack of training and education for using wearable injectors) influencing the growth of the wearable injectors market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the wearable injectors market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of wearable injectors across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the wearable injectors market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.The wearable injectors market is projected to grow from USD 11.33 billion in 2025 to USD 18.91 billion by 2030, at a CAGR of 10.8% during the forecast period. The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has created a demand for the precise, controlled, and continuous delivery of pharmacological therapies, significantly driving the growth of wearable injector technologies. Moreover, advancements in device engineering, increased spending on research and development, and the integration of the Internet of Things (IoT) and remote monitoring are enhancing patient safety and improving the efficiency of drug administration. Additionally, the shift towards home-based healthcare solutions, as opposed to traditional inpatient settings, is generating further demand for these advanced delivery systems. Furthermore, stringent regulatory frameworks surrounding wearable injectors are promoting the development of safer and more reliable systems, thereby reinforcing market expansion.
https://www.marketsandmarkets.com/Images/wearable-injector-market-Overview.webp
“The spring-based technology segment accounted for the largest share of the wearable injectors market, by technology, in 2024.”
By technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. Spring-based wearable injectors currently hold the largest share of the market because of their simple design, cost-effectiveness, and reliability. These devices utilize a mechanical spring mechanism to deliver drugs subcutaneously, which eliminates the need for complex motors or batteries. Their ease of manufacturing and reduced risk of mechanical failure make them a preferred choice for both manufacturers and patients. Furthermore, spring-based injectors are widely used in the management of chronic diseases, particularly in oncology and diabetes, where frequent and controlled dosing is crucial. The widespread adoption of these injectors in both developed and developing markets is expected to sustain their dominance through 2030.
“The disposable wearable injectors segment is expected to dominate the market, by usage, during the forecast period.”
The wearable injectors market is divided into two categories based on usage: disposable and reusable injectors. The disposable wearable injectors segment is expected to dominate the usage category during the forecast period. These devices are designed for single use, which helps reduce the risk of contamination, improve safety, and enhance patient convenience. They are especially favored in situations that require strict sterility, such as oncology treatments and the administration of biologic drugs. Additionally, the growing prevalence of biologics and personalized therapies, which often necessitate self-administration, has increased the demand for user-friendly, ready-to-use injectors. The absence of the need for maintenance, calibration, or cleaning further makes disposable injectors appealing to both patients and healthcare providers, solidifying their position as market leaders.
“The North American region is expected to capture the largest share during the forecast period.”
North America continues to be the dominant and fastest-growing region in the wearable injectors market. This growth is primarily driven by a robust healthcare infrastructure, high healthcare expenditures, and the early adoption of advanced drug delivery technologies. The US and Canada lead the way, with a significant portion of the population suffering from chronic diseases such as diabetes, cancer, and autoimmune disorders—conditions that require regular and precise medication administration. The region also benefits from a strong presence of key market players and continuous innovation in biologics and personalized medicine, both of which demand sophisticated delivery solutions like wearable injectors. Additionally, the increasing trend toward outpatient care and home-based treatment, along with favorable reimbursement policies and strong regulatory support, further accelerates market growth. Technological advancements, including the integration of digital health features and connectivity in wearable injectors, are improving treatment adherence, patient monitoring, and clinical outcomes. These developments align well with North America’s focus on value-based care, further solidifying the region’s leadership in the global wearable injectors market.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Breakdown of demand-side primary interviews:
- By Company Type: Hospitals (45%), Home Care Settings (30%), Ambulatory Surgery Centers/Specialty Infusion Centers (20%), and Other End Users (5%)
- By Designation: Healthcare Professionals (35%), Department Heads (27%), Procurement Heads (22%), and Other Designations (16%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Research Coverage
This report studies the wearable injectors market based on product, technology, usage, delivery method, therapeutic application, manufacturing type, end user, and region. It also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the market’s opportunities and challenges and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established companies and new or smaller firms understand market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.
This report provides insights into the following points:
- Analysis of key drivers (increased shift to home care settings, rising prevalence of chronic diseases, and rising aging population), restraints (high cost of wearable injectors), opportunities (high growth potential in emerging economies), and challenges (lack of training and education for using wearable injectors) influencing the growth of the wearable injectors market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the wearable injectors market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of wearable injectors across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the wearable injectors market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.
Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 MARKET SCOPE 36
1.3.1 MARKET SEGMENTATION 37
1.3.2 YEARS CONSIDERED 38
1.4 INCLUSIONS AND EXCLUSIONS 38
1.4.1 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 39
1.6 LIMITATIONS 39
1.7 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key secondary sources 44
2.1.2 PRIMARY DATA 45
2.1.2.1 Primary sources 45
2.1.2.2 Key data from primary sources 46
2.1.2.3 Key industry insights 47
2.1.2.4 Breakdown of primary interviews 47
2.2 MARKET SIZE ESTIMATION 48
2.2.1 APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 48
2.2.2 APPROACH 2: COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 51
2.2.3 APPROACH 3: BOTTOM-UP APPROACH 51
2.2.4 APPROACH 4: TOP-DOWN APPROACH 51
2.2.5 APPROACH 5: DEMAND-SIDE APPROACH 52
2.2.6 APPROACH 6: VOLUME DATA ANALYSIS 53
2.2.7 APPROACH 7: ADJACENT MARKET APPROACH 53
2.2.7.1 Injectable drug delivery market 53
2.2.7.2 Pharmaceutical drug delivery market 54
2.3 DATA TRIANGULATION 57
2.4 MARKET SHARE ESTIMATION 57
2.5 RESEARCH ASSUMPTIONS 58
2.5.1 GROWTH RATE ASSUMPTIONS 58
2.6 RISK ASSESSMENT 59
2.7 RESEARCH LIMITATIONS 59
2.7.1 METHODOLOGY-RELATED LIMITATIONS 59
2.7.2 SCOPE-RELATED LIMITATIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 68
4.1 ATTRACTIVE OPPORTUNITIES IN WEARABLE INJECTORS MARKET 68
4.2 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY APPLICATION AND COUNTRY 69
4.3 WEARABLE INJECTORS MARKET: REGIONAL MIX 70
4.4 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
4.5 WEARABLE INJECTORS MARKET: DEVELOPED VS. DEVELOPING MARKETS 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 74
5.2.1 DRIVERS 74
5.2.1.1 Rising burden of chronic diseases and aging population 74
5.2.1.2 Growing preference for home healthcare and self-administration 77
5.2.1.3 Increased number of R&D activities and strategic partnerships 77
5.2.1.4 Use of artificial intelligence in diabetes management devices 79
5.2.2 RESTRAINTS 79
5.2.2.1 High cost of wearable injectors and lack of reimbursement plans in emerging economies 79
5.2.2.2 Stringent regulatory requirements for new product approval 80
5.2.3 OPPORTUNITIES 81
5.2.3.1 Significant growth potential in emerging economies 81
5.2.3.2 Integration with digital health & remote monitoring 82
5.2.4 CHALLENGES 82
5.2.4.1 Lack of training and education for using wearable injectors 82
5.3 INDUSTRY TRENDS 83
5.3.1 INTEGRATION OF SMART CONNECTIVITY & DIGITAL HEALTH FEATURES 83
5.3.2 LARGE-VOLUME ON-BODY BIOLOGICS INJECTORS 84
5.4 TECHNOLOGY ANALYSIS 85
5.4.1 KEY TECHNOLOGIES 85
5.4.1.1 Micro-MEMS and Bio-MEMS in wearable injectors 85
5.4.1.2 Electromechanical drive systems (motorized pumps) 85
5.4.1.3 Sensor-integrated closed-loop wearable injector 86
5.4.2 COMPLEMENTARY TECHNOLOGIES 86
5.4.2.1 Smartphone and app interfaces 86
5.4.2.2 IoT and smart analytics in wearable injectors 87
5.4.3 ADJACENT TECHNOLOGIES 88
5.4.3.1 Electrochemical aptamer biosensors 88
5.4.3.2 Telemedicine platforms 88
5.5 PORTER’S FIVE FORCES ANALYSIS 89
5.5.1 THREAT OF NEW ENTRANTS 90
5.5.2 THREAT OF SUBSTITUTES 90
5.5.3 BARGAINING POWER OF SUPPLIERS 90
5.5.4 BARGAINING POWER OF BUYERS 91
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 91
5.6 PIPELINE ANALYSIS 91
5.7 REGULATORY LANDSCAPE 92
5.7.1 REGULATORY ANALYSIS 92
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.8 PATENT ANALYSIS 96
5.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS 96
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 97
5.9 TRADE ANALYSIS 99
5.9.1 TRADE DATA FOR HS CODE 901890 99
5.9.1.1 Import data for HS Code 901890 99
5.9.1.2 Export data for HS Code 901890 100
5.10 PRICING ANALYSIS 100
5.10.1 AVERAGE SELLING PRICE, BY KEY PLAYER 100
5.10.1.1 Average selling price trend among key players 101
5.10.2 AVERAGE SELLING PRICE, BY REGION 102
5.10.2.1 Average selling price trend of on-body wearable injector, by region 103
5.10.2.2 Average selling price trend of off-body wearable injector, by region 103
5.11 REIMBURSEMENT ANALYSIS 103
5.12 KEY CONFERENCES & EVENTS, 2025–2026 105
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 106
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES) 106
5.13.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS) 107
5.13.3 BUYING CRITERIA 107
5.14 UNMET NEEDS/END-USER EXPECTATIONS 109
5.15 IMPACT OF AI ON WEARABLE INJECTORS MARKET 109
5.15.1 INTRODUCTION 109
5.15.2 MARKET POTENTIAL IN WEARABLE INJECTORS ECOSYSTEM 110
5.15.3 AI USE CASES 110
5.15.4 KEY COMPANIES IMPLEMENTING AI IN WEARABLE INJECTORS 111
5.15.5 FUTURE OF GEN AI IN WEARABLE INJECTORS ECOSYSTEM 111
5.16 ECOSYSTEM ANALYSIS 112
5.16.1 WEARABLE INJECTOR PROVIDERS 112
5.16.2 END USERS 114
5.16.3 REGULATORY BODIES 114
5.17 VALUE CHAIN ANALYSIS 115
5.18 INVESTMENT AND FUNDING SCENARIO 116
5.19 IMPACT OF 2025 US TARIFF 117
5.19.1 INTRODUCTION 117
5.19.2 KEY TARIFF RATES 118
5.19.3 PRICE IMPACT ANALYSIS 119
5.19.4 IMPACT ON COUNTRY/REGION 119
5.19.5 IMPACT ON END-USE INDUSTRIES 121
5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 122
6 WEARABLE INJECTORS MARKET, BY PRODUCT 123
6.1 INTRODUCTION 124
6.2 ON-BODY WEARABLE INJECTORS 125
6.2.1 LARGE-VOLUME SUBCUTANEOUS DELIVERY AND HOME-BASED CARE TO DRIVE MARKET 125
6.3 OFF-BODY WEARABLE INJECTORS 128
6.3.1 TECHNOLOGICAL VERSATILITY AND PERSONALIZED DRUG DELIVERY TO DRIVE MARKET 128
7 WEARABLE INJECTORS MARKET, BY DELIVERY METHOD 131
7.1 INTRODUCTION 132
7.2 PROGRAMMED/CONTINUOUS INFUSION 133
7.2.1 NEED FOR PRECISE, CONTROLLED DRUG DELIVERY OVER EXTENDED DURATIONS TO DRIVE SEGMENT 133
7.3 BOLUS-ONLY 135
7.3.1 GROWING DEMAND FOR SELF-ADMINISTERED, SINGLE-DOSE BIOLOGICS TO DRIVE SEGMENT GROWTH 135
8 WEARABLE INJECTORS MARKET, BY END USER 137
8.1 INTRODUCTION 138
8.2 WEARABLE INJECTOR FORMULATION END USERS 138
8.2.1 HOME CARE SETTINGS 141
8.2.1.1 RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET 141
8.2.2 HOSPITALS & CLINICS 143
8.2.2.1 Increased hospital demand for controlled drug delivery boosting market uptake 143
8.2.3 SPECIALTY INFUSION CENTERS/AMBULATORY SURGERY CENTERS 145
8.2.3.1 Cost-efficiency to drive demand for wearable injectors in specialty centers 145
8.2.4 OTHER FORMULATION END USERS 147
8.3 WEARABLE INJECTOR DEVICE END USERS 149
8.3.1 PHARMACEUTICAL COMPANIES 151
8.3.1.1 Need for efficient subcutaneous delivery of large-volume biologics to drive market 151
8.3.2 BIOTECHNOLOGY COMPANIES 153
8.3.2.1 Improved patient experience, dose accuracy, and at-home administration of complex biologics to drive market 153
8.3.3 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 155
8.3.3.1 Innovation through cost-effective and scalable manufacturing solutions to drive market 155
9 WEARABLE INJECTORS MARKET, BY TECHNOLOGY 157
9.1 INTRODUCTION 158
9.2 SPRING-BASED TECHNOLOGY 159
9.2.1 COST-EFFECTIVE ENGINEERING AND MECHANICAL SIMPLICITY TO DRIVE MARKET 159
9.3 MOTOR-DRIVEN TECHNOLOGY 162
9.3.1 PRECISION DOSING AND PROGRAMMABILITY ACCELERATING ADOPTION OF MOTOR-BASED WEARABLE INJECTORS 162
9.4 ROTARY PUMP TECHNOLOGY 164
9.4.1 HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH 164
9.5 EXPANDING BATTERY TECHNOLOGY 166
9.5.1 SHIFT TOWARD HIGH-VOLUME DELIVERY OF VISCOUS DRUGS TO BOOST DEMAND 166
9.6 OTHER TECHNOLOGIES 168
10 WEARABLE INJECTORS MARKET, BY THERAPEUTIC APPLICATION 170
10.1 INTRODUCTION 171
10.2 AUTOIMMUNE DISEASES 172
10.2.1 GROWING PREFERENCE FOR SELF-ADMINISTRATION IN CHRONIC AUTOIMMUNE DISORDERS TO FUEL DEMAND 172
10.3 DIABETES 175
10.3.1 HIGH DISEASE BURDEN AND DAILY INJECTION DEMAND FUEL MARKET DOMINANCE 175
10.4 ONCOLOGY 178
10.4.1 INCREASING NUMBER OF CANCER CASES, SHIFT TOWARD SUBCUTANEOUS CANCER THERAPIES, AND NEED TO REDUCE HOSPITAL BURDEN TO BOOST MARKET 178
10.5 CARDIOVASCULAR DISEASES 180
10.5.1 RISING NEED FOR CONTINUOUS DRUG DELIVERY IN PULMONARY AND CARDIORENAL CONDITIONS TO DRIVE DEMAND 180
10.6 INFECTIOUS DISEASES 182
10.6.1 NEED FOR RAPID AND SELF-ADMINISTERED TREATMENT TO DRIVE ADOPTION 182
10.7 RARE/ORPHAN DISEASES 184
10.7.1 HIGH-COST BIOLOGICS AND PERSONALIZED TREATMENT NEEDS TO DRIVE DEMAND 184
10.8 OTHER THERAPEUTIC APPLICATIONS 186
11 WEARABLE INJECTORS MARKET, BY USAGE 188
11.1 INTRODUCTION 189
11.2 DISPOSABLE 190
11.2.1 RISING PREFERENCE FOR SIMPLICITY, STERILITY, AND SINGLE-USE SAFETY TO DRIVE DISPOSABLE WEARABLE INJECTORS MARKET 190
11.3 REUSABLE 192
11.3.1 ENABLING LONG-TERM COST EFFICIENCY AND SUSTAINABLE DRUG DELIVERY MODELS TO DRIVE DEMAND 192
12 WEARABLE INJECTORS MARKET, BY REGION 194
12.1 INTRODUCTION 195
12.2 NORTH AMERICA 196
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 197
12.2.2 US 204
12.2.2.1 Growing home healthcare market to drive demand 204
12.2.3 CANADA 209
12.2.3.1 Rising biologic usage and decentralized care pathways to boost demand 209
12.3 EUROPE 213
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 214
12.3.2 GERMANY 220
12.3.2.1 Domestic medtech innovation and government initiatives to fuel growth 220
12.3.3 UK 225
12.3.3.1 NHS digital strategy and homecare shift to accelerate wearable injector adoption 225
12.3.4 FRANCE 230
12.3.4.1 Well-established healthcare system to support market growth 230
12.3.5 ITALY 235
12.3.5.1 Growing demand for cost-effective home care to drive market 235
12.3.6 SPAIN 240
12.3.6.1 Rising prevalence of cancer to drive demand 240
12.3.7 NETHERLANDS 244
12.3.7.1 Strong healthcare infrastructure and aging population to drive market growth 244
12.3.8 REST OF EUROPE 249
12.4 ASIA PACIFIC 254
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 254
12.4.2 CHINA 260
12.4.2.1 Growing investments in healthcare infrastructure to drive market 260
12.4.3 JAPAN 265
12.4.3.1 Large geriatric population to drive demand 265
12.4.4 INDIA 270
12.4.4.1 Increasing demand for advanced medical treatment to boost market 270
12.4.5 AUSTRALIA 274
12.4.5.1 Rising prevalence of chronic diseases to fuel market 274
12.4.6 THAILAND 279
12.4.6.1 Expansion of universal healthcare to drive growth of wearable injectors market 279
12.4.7 VIETNAM 283
12.4.7.1 Rapidly aging population to drive demand 283
12.4.8 SOUTH KOREA 288
12.4.8.1 Rise of geriatric population to drive growth 288
12.4.9 INDONESIA 292
12.4.9.1 Growing emphasis on home-based care and universal coverage to drive adoption of wearable injectors 292
12.4.10 REST OF ASIA PACIFIC 297
12.5 LATIN AMERICA 301
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 301
12.5.2 BRAZIL 307
12.5.2.1 Increasing number of chronic conditions to drive market 307
12.5.3 MEXICO 312
12.5.3.1 Government initiatives to boost wearable injectors market 312
12.5.4 REST OF LATIN AMERICA 317
12.6 MIDDLE EAST & AFRICA 322
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 322
12.6.2 GCC COUNTRIES 327
12.6.2.1 Kingdom of Saudi Arabia (KSA) 332
12.6.2.1.1 Smart healthcare infrastructure and chronic disease burden to propel market expansion 332
12.6.2.2 United Arab Emirates (UAE) 336
12.6.2.2.1 Government support and digital health initiatives to fuel UAE’s wearable injectors market 336
12.6.2.3 Rest of GCC Countries 341
12.6.3 REST OF MIDDLE EAST & AFRICA 345
13 COMPETITIVE LANDSCAPE 350
13.1 OVERVIEW 350
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 350
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN WEARABLE INJECTORS MARKET 351
13.3 REVENUE ANALYSIS, 2020−2024 353
13.3.1 WEARABLE INJECTOR DEVICE MANUFACTURERS 353
13.3.2 WEARABLE INJECTOR FORMULATION MANUFACTURERS 353
13.4 MARKET SHARE ANALYSIS 354
13.4.1 WEARABLE INJECTOR DEVICE MANUFACTURERS 354
13.4.2 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024 355
13.4.3 US MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024 356
13.4.4 WEARABLE INJECTOR FORMULATION MANUFACTURERS 357
13.4.5 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024 358
13.4.6 US MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024 359
13.5 COMPANY EVALUATION MATRIX: DEVICE KEY PLAYERS, 2024 360
13.5.1 STARS 361
13.5.2 EMERGING LEADERS 361
13.5.3 PERVASIVE PLAYERS 361
13.5.4 PARTICIPANTS 361
13.5.5 COMPANY FOOTPRINT: DEVICE KEY PLAYERS, 2024 363
13.5.5.1 Company footprint 363
13.5.5.2 Region footprint 364
13.5.5.3 Product type footprint 364
13.5.5.4 Usage footprint 365
13.5.5.5 Delivery method footprint 365
13.5.5.6 Technology type footprint 366
13.6 COMPANY EVALUATION MATRIX: DEVICE STARTUPS/SMES, 2024 367
13.6.1 PROGRESSIVE COMPANIES 367
13.6.2 DYNAMIC COMPANIES 367
13.6.3 STARTING BLOCKS 367
13.6.4 RESPONSIVE COMPANIES 367
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 369
13.6.5.1 Detailed list of key device startups/SME players 369
13.6.5.2 Competitive benchmarking of key SMEs/startups 369
13.7 COMPANY EVALUATION MATRIX: FORMULATION KEY PLAYERS, 2024 370
13.7.1 STARS 370
13.7.2 EMERGING LEADERS 370
13.7.3 PERVASIVE PLAYERS 370
13.7.4 PARTICIPANTS 370
13.7.5 COMPANY FOOTPRINT: FORMULATION KEY PLAYERS, 2024 372
13.7.5.1 Company footprint 372
13.7.5.2 Region footprint 372
13.7.5.3 Product type footprint 373
13.7.5.4 Delivery method footprint 373
13.7.5.5 Therapeutic application footprint 374
13.7.5.6 Technology type footprint 374
13.8 BRAND/PRODUCT COMPARISON 375
13.9 R&D EXPENDITURE OF KEY PLAYERS 376
13.10 COMPANY VALUATION AND FINANCIAL METRICS 376
13.10.1 COMPANY VALUATION 376
13.10.2 FINANCIAL METRICS 377
13.11 COMPETITIVE SCENARIO 377
13.11.1 PRODUCT LAUNCHES & APPROVALS 377
13.11.2 DEALS 378
13.11.3 EXPANSIONS 379
13.11.4 OTHER DEVELOPMENTS 380
14 COMPANY PROFILES 381
14.1 WEARABLE INJECTORS DEVICE MANUFACTURERS 381
14.2 KEY PLAYERS 381
14.2.1 INSULET CORPORATION 381
14.2.1.1 Business overview 381
14.2.1.2 Products/Solutions/Services offered 382
14.2.1.3 Recent developments 383
14.2.1.3.1 Product launches, upgrades, and approvals 383
14.2.1.3.2 Deals 384
14.2.1.3.3 Expansions 384
14.2.1.4 MnM view 385
14.2.1.4.1 Key strengths 385
14.2.1.4.2 Strategic choices 385
14.2.1.4.3 Weaknesses & competitive threats 385
14.2.2 TANDEM DIABETES CARE, INC. 386
14.2.2.1 Business overview 386
14.2.2.2 Products/Solutions/Services offered 387
14.2.2.3 Recent developments 388
14.2.2.3.1 Product launches, upgrades, and approvals 388
14.2.2.3.2 Deals 389
14.2.2.4 MnM view 390
14.2.2.4.1 Key strengths 390
14.2.2.4.2 Strategic choices 390
14.2.2.4.3 Weaknesses & competitive threats 390
14.2.3 MEDTRONIC 391
14.2.3.1 Business overview 391
14.2.3.2 Products/Solutions/Services offered 392
14.2.3.3 Recent developments 393
14.2.3.3.1 Product launches, upgrades, and approvals 393
14.2.3.3.2 Deals 393
14.2.3.4 MnM view 394
14.2.3.4.1 Key strengths 394
14.2.3.4.2 Strategic choices 394
14.2.3.4.3 Weaknesses & competitive threats 394
14.2.4 BD 395
14.2.4.1 Business overview 395
14.2.4.2 Products/Solutions/Services offered 396
14.2.4.3 Recent developments 397
14.2.4.3.1 Deals 397
14.2.4.3.2 Expansions 397
14.2.4.3.3 Other developments 398
14.2.4.4 MnM view 398
14.2.4.4.1 Key strengths 398
14.2.4.4.2 Strategic choices 398
14.2.4.4.3 Weaknesses & competitive threats 398
14.2.5 WEST PHARMACEUTICAL SERVICES, INC. 399
14.2.5.1 Business overview 399
14.2.5.2 Products/Solutions/Services offered 400
14.2.5.3 Recent developments 401
14.2.5.3.1 Expansions 401
14.2.5.4 MnM view 402
14.2.5.4.1 Key strengths 402
14.2.5.4.2 Strategic choices 402
14.2.5.4.3 Weaknesses & competitive threats 402
14.2.6 GERRESHEIMER AG 403
14.2.6.1 Business overview 403
14.2.6.2 Products/Solutions/Services offered 404
14.2.6.3 Recent developments 405
14.2.6.3.1 Expansions 405
14.2.7 STEVANATO 406
14.2.7.1 Business overview 406
14.2.7.2 Products/Solutions/Services offered 407
14.2.7.3 Recent developments 408
14.2.7.3.1 Product launches, upgrades, and approvals 408
14.2.7.3.2 Deals 408
14.2.8 LTS LOHMANN THERAPIE-SYSTEME AG 409
14.2.8.1 Business overview 409
14.2.8.2 Products/Solutions/Services offered 409
14.2.8.3 Recent developments 410
14.2.8.3.1 Product launches, upgrades, and approvals 410
14.2.8.3.2 Deals 410
14.2.8.3.3 Expansions 411
14.2.9 SONCEBOZ 412
14.2.9.1 Business overview 412
14.2.9.2 Products/Solutions/Services offered 412
14.2.10 NEMERA 413
14.2.10.1 Business overview 413
14.2.10.2 Products/Solutions/Services offered 413
14.2.10.3 Recent developments 414
14.2.10.3.1 Deals 414
14.2.10.3.2 Expansions 414
14.2.11 MANNKIND CORPORATION 415
14.2.11.1 Business overview 415
14.2.11.2 Products/Solutions/Services offered 416
14.2.11.3 Recent developments 416
14.2.11.3.1 Deals 416
14.2.12 ENABLE INJECTIONS, INC. 417
14.2.12.1 Business overview 417
14.2.12.2 Products/Solutions/Services offered 417
14.2.12.3 Recent developments 418
14.2.12.3.1 Product launches, upgrades, and approvals 418
14.2.12.3.2 Deals 418
14.2.12.3.3 Expansions 419
14.2.12.3.4 Other developments 419
14.2.13 ELCAM MEDICAL 420
14.2.13.1 Business overview 420
14.2.13.2 Products/Solutions/Services offered 420
14.2.13.3 Recent developments 421
14.2.13.3.1 Expansions 421
14.3 OTHER PLAYERS 422
14.3.1 DEBIOTECH SA 422
14.3.2 MEDTRUM TECHNOLOGIES INC. 423
14.3.3 CEQUR SIMPLICITY 424
14.3.4 SUBCUJECT APS 425
14.3.5 MICROMED CO., LTD 425
14.4 WEARABLE INJECTORS WITH FORMULATION MANUFACTURERS 426
14.4.1 AMGEN INC. 426
14.4.1.1 Business overview 426
14.4.1.2 Products/Solutions/Services offered 427
14.4.1.3 Recent developments 427
14.4.1.3.1 Deals 427
14.4.1.3.2 Expansions 428
14.4.2 ABBVIE INC. 429
14.4.2.1 Business overview 429
14.4.2.2 Products/Solutions/Services offered 430
14.4.2.3 Recent developments 431
14.4.2.3.1 Product launches, upgrades, and approvals 431
14.4.2.3.2 Expansions 432
14.4.3 UNITED THERAPEUTICS CORPORATION 433
14.4.3.1 Business overview 433
14.4.3.2 Products/Solutions/Services offered 434
14.4.3.3 Recent developments 434
14.4.3.3.1 Expansions 434
14.4.4 APELLIS PHARMACEUTICALS, INC. 435
14.4.4.1 Business overview 435
14.4.4.2 Products/Solutions/Services offered 436
14.4.4.3 Recent developments 436
14.4.4.3.1 Product launches, upgrades, and approvals 436
14.4.5 SUPERNUS PHARMACEUTICALS 437
14.4.5.1 Business overview 437
14.4.5.2 Products/Solutions/Services offered 438
14.4.5.3 Recent developments 438
14.4.5.3.1 Product launches, upgrades, and approvals 438
14.4.6 COHERUS BIOSCIENCES, INC. 439
14.4.6.1 Business overview 439
14.4.6.2 Products/Solutions/Services offered 440
14.4.6.3 Recent developments 440
14.4.6.3.1 Product launches, upgrades, and approvals 440
14.4.6.3.2 Other developments 440
14.4.7 SCPHARMACEUTICALS, INC. 441
14.4.7.1 Business overview 441
14.4.7.2 Products/Solutions/Services offered 442
14.4.7.3 Recent developments 442
14.4.7.3.1 Product launches, upgrades and approvals 442
15 APPENDIX 443
15.1 DISCUSSION GUIDE 443
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 448
15.3 CUSTOMIZATION OPTIONS 450
15.4 RELATED REPORTS 450
15.5 AUTHOR DETAILS 451
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 39
TABLE 2 RISK ASSESSMENT: WEARABLE INJECTORS MARKET 59
TABLE 3 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS
(20–79 YEARS), 2021 VS. 2045 75
TABLE 4 RECENT DEVELOPMENTS IN SMART WEARABLE INJECTORS 84
TABLE 5 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 89
TABLE 6 WEARABLE INJECTORS IN CLINICAL PIPELINE 92
TABLE 7 STRINGENCY OF REGULATIONS FOR WEARABLE INJECTORS, BY REGION 93
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 14 WEARABLE INJECTORS MARKET: MAJOR PATENTS 98
TABLE 15 IMPORT DATA FOR HS CODE 901890, BY COUNTRY,
2021–2024 (USD THOUSAND) 99
TABLE 16 EXPORT DATA FOR HS CODE 901890, BY COUNTRY,
2021–2024 (USD THOUSAND) 100
TABLE 17 AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYER, 2024 100
TABLE 18 AVERAGE SELLING PRICE TRENDS AMONG KEY PLAYERS, BY PRODUCT,
2022–2024 101
TABLE 19 AVERAGE SELLING PRICE TREND OF ON-BODY WEARABLE INJECTOR, BY REGION, 2022–2024 103
TABLE 20 AVERAGE SELLING PRICE TREND FOR OFF-BODY WEARABLE INJECTOR,
BY REGION, 2022–2024 103
TABLE 21 WEARABLE INJECTORS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 105
TABLE 22 WEARABLE INJECTORS MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (DEVICES) 106
TABLE 23 WEARABLE INJECTORS MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (FORMULATIONS) 107
TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 108
TABLE 25 KEY COMPANIES IMPLEMENTING AI IN WEARABLE INJECTORS 111
TABLE 26 LIST OF KEY WEARABLE INJECTOR DEVICE PROVIDERS 113
TABLE 27 LIST OF KEY WEARABLE INJECTOR FORMULATION PROVIDERS 113
TABLE 28 LIST OF KEY END USERS 114
TABLE 29 LIST OF KEY REGULATORY BODIES 114
TABLE 30 US ADJUSTED RECIPROCAL TARIFF RATES 118
TABLE 31 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR WEARABLE INJECTOR DEVICES 118
TABLE 32 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 119
TABLE 33 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 120
TABLE 34 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 121
TABLE 35 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 121
TABLE 36 KEY PLAYERS PROVIDING WEARABLE INJECTORS, BY PRODUCT 124
TABLE 37 WEARABLE INJECTORS MARKET, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 38 KEY PLAYERS PROVIDING ON-BODY WEARABLE INJECTORS 126
TABLE 39 WEARABLE INJECTORS MARKET FOR ON-BODY INJECTORS, BY REGION,
2023–2030 (THOUSAND UNITS) 126
TABLE 40 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 41 KEY PLAYERS PROVIDING OFF-BODY WEARABLE INJECTORS 128
TABLE 42 WEARABLE INJECTORS MARKET FOR OFF-BODY INJECTORS, BY REGION,
2023–2030 (THOUSAND UNITS) 129
TABLE 43 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 44 WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 132
TABLE 45 WEARABLE INJECTORS MARKET FOR PROGRAMMED/CONTINUOUS INFUSION DELIVERY METHOD, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 46 WEARABLE INJECTORS MARKET FOR BOLUS-ONLY DELIVERY METHOD,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 47 WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 138
TABLE 48 WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 139
TABLE 49 WEARABLE INJECTORS MARKET FOR FORMULATION END USER, BY COUNTRY 2023–2030 (USD MILLION) 140
TABLE 50 WEARABLE INJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 51 WEARABLE INJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 52 WEARABLE INJECTORS MARKET FOR SPECIALTY INFUSION CENTERS/AMBULATORY SURGERY CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 53 WEARABLE INJECTORS MARKET FOR OTHER FORMULATION END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 54 WEARABLE INJECTOR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 149
TABLE 55 WEARABLE INJECTOR MARKET FOR DEVICE END USER, BY COUNTRY
2023–2030 (USD MILLION) 150
TABLE 56 WEARABLE INJECTORS MARKET FOR PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 57 WEARABLE INJECTORS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 58 WEARABLE INJECTORS MARKET FOR CDMOS, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 59 KEY PLAYERS PROVIDING WEARABLE INJECTORS, BY TECHNOLOGY 158
TABLE 60 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 159
TABLE 61 KEY PLAYERS PROVIDING SPRING-BASED WEARABLE INJECTORS 160
TABLE 62 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 63 KEY PLAYERS PROVIDING MOTOR-BASED WEARABLE INJECTORS 162
TABLE 64 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 65 KEY PLAYERS PROVIDING ROTARY PUMP WEARABLE INJECTORS 164
TABLE 66 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 67 KEY PLAYERS PROVIDING EXPANDING BATTERY WEARABLE INJECTORS 166
TABLE 68 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 69 KEY PLAYERS PROVIDING OTHER TECHNOLOGIES WEARABLE INJECTORS 168
TABLE 70 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 71 KEY PLAYERS PROVIDING WEARABLE INJECTORS, BY THERAPEUTIC APPLICATION 171
TABLE 72 WEARABLE INJECTORS MARKET, BY THERAPEUTIC APPLICATION,
2023–2030 (USD MILLION) 172
TABLE 73 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR AUTOIMMUNE DISEASES 173
TABLE 74 WEARABLE INJECTORS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 75 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR DIABETES 176
TABLE 76 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 77 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR ONCOLOGY 178
TABLE 78 WEARABLE INJECTORS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 179
TABLE 79 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR CARDIOVASCULAR DISEASES 180
TABLE 80 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 81 WEARABLE INJECTORS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2023–2030 (USD MILLION) 183
TABLE 82 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR RARE/ORPHAN DISEASES 184
TABLE 83 WEARABLE INJECTORS MARKET FOR RARE/ORPHAN DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 84 KEY PLAYERS PROVIDING WEARABLE INJECTORS FOR OTHER THERAPEUTIC APPLICATIONS 186
TABLE 85 WEARABLE INJECTORS MARKET FOR OTHER THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 86 KEY PLAYERS PROVIDING WEARABLE INJECTORS, BY USAGE 189
TABLE 87 WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 190
TABLE 88 KEY PLAYERS PROVIDING DISPOSABLE WEARABLE INJECTORS 190
TABLE 89 WEARABLE INJECTORS MARKET FOR DISPOSABLE WEARABLE INJECTORS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 90 KEY PLAYERS PROVIDING REUSABLE WEARABLE INJECTORS 192
TABLE 91 WEARABLE INJECTORS MARKET FOR REUSABLE WEARABLE INJECTORS,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 92 WEARABLE INJECTORS MARKET, BY REGION, 2023–2030 (USD MILLION) 196
TABLE 93 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 199
TABLE 94 WEARABLE INJECTORS MARKET FOR NORTH AMERICA, BY PRODUCT,
2023–2030 (THOUSAND UNITS) 199
TABLE 95 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 200
TABLE 96 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 200
TABLE 97 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 201
TABLE 98 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 201
TABLE 99 NORTH AMERICA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 202
TABLE 100 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 202
TABLE 101 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 203
TABLE 102 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 203
TABLE 103 US: KEY MACROINDICATORS 204
TABLE 104 US: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 205
TABLE 105 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 205
TABLE 106 US: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 206
TABLE 107 US: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 206
TABLE 108 US: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 207
TABLE 109 US: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 207
TABLE 110 US: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 208
TABLE 111 US: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 208
TABLE 112 CANADA: KEY MACROINDICATORS 209
TABLE 113 CANADA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 210
TABLE 114 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 210
TABLE 115 CANADA: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 211
TABLE 116 CANADA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 211
TABLE 117 CANADA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 212
TABLE 118 CANADA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 212
TABLE 119 CANADA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 213
TABLE 120 CANADA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 213
TABLE 121 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 215
TABLE 122 WEARABLE INJECTORS MARKET FOR EUROPE, BY PRODUCT,
2023–2030 (THOUSAND UNITS) 215
TABLE 123 EUROPE: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 216
TABLE 124 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 216
TABLE 125 EUROPE: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 217
TABLE 126 EUROPE: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 217
TABLE 127 EUROPE: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 218
TABLE 128 EUROPE: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 129 EUROPE: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 219
TABLE 130 EUROPE: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 219
TABLE 131 GERMANY: KEY MACROINDICATORS 221
TABLE 132 GERMANY: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 221
TABLE 133 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 222
TABLE 134 GERMANY: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 222
TABLE 135 GERMANY: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 223
TABLE 136 GERMANY: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 223
TABLE 137 GERMANY: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 224
TABLE 138 GERMANY: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 224
TABLE 139 GERMANY: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 225
TABLE 140 UK: KEY MACROINDICATORS 226
TABLE 141 UK: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 226
TABLE 142 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 227
TABLE 143 UK: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 227
TABLE 144 UK: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 228
TABLE 145 UK: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 228
TABLE 146 UK: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 229
TABLE 147 UK: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 229
TABLE 148 UK: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 230
TABLE 149 FRANCE: KEY MACROINDICATORS 231
TABLE 150 FRANCE: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 231
TABLE 151 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 232
TABLE 152 FRANCE: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 232
TABLE 153 FRANCE: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 233
TABLE 154 FRANCE: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 233
TABLE 155 FRANCE: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 234
TABLE 156 FRANCE: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 234
TABLE 157 FRANCE: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 235
TABLE 158 ITALY: KEY MACROINDICATORS 236
TABLE 159 ITALY: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 236
TABLE 160 ITALY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 237
TABLE 161 ITALY: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 237
TABLE 162 ITALY: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 238
TABLE 163 ITALY: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 238
TABLE 164 ITALY: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 239
TABLE 165 ITALY: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 239
TABLE 166 ITALY: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 240
TABLE 167 SPAIN: KEY MACROINDICATORS 240
TABLE 168 SPAIN: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 241
TABLE 169 SPAIN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 241
TABLE 170 SPAIN: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 242
TABLE 171 SPAIN: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 242
TABLE 172 SPAIN: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 173 SPAIN: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 243
TABLE 174 SPAIN: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 244
TABLE 175 SPAIN: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 244
TABLE 176 NETHERLANDS: KEY MACROINDICATORS 245
TABLE 177 NETHERLANDS: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 245
TABLE 178 NETHERLANDS: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 246
TABLE 179 NETHERLANDS: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 246
TABLE 180 NETHERLANDS: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 247
TABLE 181 NETHERLANDS: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 247
TABLE 182 NETHERLANDS: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 248
TABLE 183 NETHERLANDS: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 248
TABLE 184 NETHERLANDS: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 249
TABLE 185 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 250
TABLE 186 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 250
TABLE 187 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 251
TABLE 188 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 251
TABLE 189 REST OF EUROPE: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 252
TABLE 190 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 252
TABLE 191 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 253
TABLE 192 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 253
TABLE 193 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 256
TABLE 194 WEARABLE INJECTORS MARKET FOR ASIA-PACIFIC, BY PRODUCT,
2023–2030 (THOUSAND UNITS) 256
TABLE 195 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 257
TABLE 196 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 257
TABLE 197 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 258
TABLE 198 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 258
TABLE 199 ASIA PACIFIC: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 259
TABLE 200 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 259
TABLE 201 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 260
TABLE 202 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 260
TABLE 203 CHINA: MACROECONOMIC INDICATORS 261
TABLE 204 CHINA: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 262
TABLE 205 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 262
TABLE 206 CHINA: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 263
TABLE 207 CHINA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 263
TABLE 208 CHINA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 264
TABLE 209 CHINA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 264
TABLE 210 CHINA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 265
TABLE 211 CHINA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 265
TABLE 212 JAPAN: MACROECONOMIC INDICATORS 266
TABLE 213 JAPAN: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 266
TABLE 214 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 267
TABLE 215 JAPAN: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 267
TABLE 216 JAPAN: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 268
TABLE 217 JAPAN: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 268
TABLE 218 JAPAN: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 269
TABLE 219 JAPAN: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 269
TABLE 220 JAPAN: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 270
TABLE 221 INDIA: MACROECONOMIC INDICATORS 271
TABLE 222 INDIA: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 271
TABLE 223 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 271
TABLE 224 INDIA: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 272
TABLE 225 INDIA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 272
TABLE 226 INDIA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 273
TABLE 227 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 273
TABLE 228 INDIA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 274
TABLE 229 INDIA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 274
TABLE 230 AUSTRALIA: KEY MACROINDICATORS 275
TABLE 231 AUSTRALIA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 275
TABLE 232 AUSTRALIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 276
TABLE 233 AUSTRALIA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 276
TABLE 234 AUSTRALIA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 277
TABLE 235 AUSTRALIA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 277
TABLE 236 AUSTRALIA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 278
TABLE 237 AUSTRALIA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 278
TABLE 238 AUSTRALIA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 279
TABLE 239 THAILAND: MACROECONOMIC INDICATORS 280
TABLE 240 THAILAND: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 280
TABLE 241 THAILAND: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 280
TABLE 242 THAILAND: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 281
TABLE 243 THAILAND: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 281
TABLE 244 THAILAND: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 282
TABLE 245 THAILAND: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 282
TABLE 246 THAILAND: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 283
TABLE 247 THAILAND: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 283
TABLE 248 VIETNAM: MACROECONOMIC INDICATORS 284
TABLE 249 VIETNAM: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 284
TABLE 250 VIETNAM: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 285
TABLE 251 VIETNAM: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 285
TABLE 252 VIETNAM: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 286
TABLE 253 VIETNAM: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 286
TABLE 254 VIETNAM: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 287
TABLE 255 VIETNAM: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 287
TABLE 256 VIETNAM: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 288
TABLE 257 SOUTH KOREA: MACROECONOMIC INDICATORS 288
TABLE 258 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 289
TABLE 259 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 289
TABLE 260 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 290
TABLE 261 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 290
TABLE 262 SOUTH KOREA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 291
TABLE 263 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 291
TABLE 264 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 292
TABLE 265 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 292
TABLE 266 INDONESIA: MACROECONOMIC INDICATORS 293
TABLE 267 INDONESIA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 293
TABLE 268 INDONESIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 294
TABLE 269 INDONESIA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 294
TABLE 270 INDONESIA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 295
TABLE 271 INDONESIA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 295
TABLE 272 INDONESIA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 296
TABLE 273 INDONESIA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 296
TABLE 274 INDONESIA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 297
TABLE 275 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 297
TABLE 276 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 298
TABLE 277 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 298
TABLE 278 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 299
TABLE 279 REST OF ASIA PACIFIC: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 299
TABLE 280 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 300
TABLE 281 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 300
TABLE 282 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 301
TABLE 283 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 302
TABLE 284 WEARABLE INJECTORS MARKET FOR LATIN AMERICA, BY PRODUCT,
2023–2030 (THOUSAND UNITS) 303
TABLE 285 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 303
TABLE 286 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 304
TABLE 287 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 304
TABLE 288 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 305
TABLE 289 LATIN AMERICA: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 305
TABLE 290 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 306
TABLE 291 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 306
TABLE 292 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 307
TABLE 293 BRAZIL: MACROECONOMIC INDICATORS 308
TABLE 294 BRAZIL: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 308
TABLE 295 BRAZIL: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 309
TABLE 296 BRAZIL: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 309
TABLE 297 BRAZIL: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 310
TABLE 298 BRAZIL: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 310
TABLE 299 BRAZIL: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 311
TABLE 300 BRAZIL: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 311
TABLE 301 BRAZIL: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 312
TABLE 302 MEXICO: MACROECONOMIC INDICATORS 313
TABLE 303 MEXICO: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 313
TABLE 304 MEXICO: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 314
TABLE 305 MEXICO: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 314
TABLE 306 MEXICO: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 315
TABLE 307 MEXICO: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 315
TABLE 308 MEXICO: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 316
TABLE 309 MEXICO: WEARABLE INJECTORS MARKET, BY FORMULATION END USER,
2023–2030 (USD MILLION) 316
TABLE 310 MEXICO: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 317
TABLE 311 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 318
TABLE 312 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 318
TABLE 313 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 319
TABLE 314 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 319
TABLE 315 REST OF LATIN AMERICA: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 320
TABLE 316 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 320
TABLE 317 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 321
TABLE 318 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 321
TABLE 319 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 323
TABLE 320 WEARABLE INJECTORS MARKET FOR MIDDLE EAST & AFRICA, BY PRODUCT, 2023–2030 (THOUSAND UNITS) 323
TABLE 321 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 323
TABLE 322 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 324
TABLE 323 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 324
TABLE 324 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 325
TABLE 325 MIDDLE EAST & AFRICA: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 325
TABLE 326 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 326
TABLE 327 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 326
TABLE 328 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 327
TABLE 329 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 328
TABLE 330 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 328
TABLE 331 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 329
TABLE 332 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 329
TABLE 333 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD,
2023–2030 (USD MILLION) 330
TABLE 334 GCC COUNTRIES: WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 330
TABLE 335 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 331
TABLE 336 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 331
TABLE 337 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY DEVICE END USER,
2023–2030 (USD MILLION) 332
TABLE 338 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROINDICATORS 333
TABLE 339 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 333
TABLE 340 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 333
TABLE 341 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 334
TABLE 342 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 334
TABLE 343 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 335
TABLE 344 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 335
TABLE 345 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 336
TABLE 346 KINGDOM OF SAUDI ARABIA: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 336
TABLE 347 UAE: KEY MACROINDICATORS 337
TABLE 348 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 337
TABLE 349 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 338
TABLE 350 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 338
TABLE 351 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 339
TABLE 352 UNITED ARAB EMIRATES: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 339
TABLE 353 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 340
TABLE 354 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 340
TABLE 355 UNITED ARAB EMIRATES: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 341
TABLE 356 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 342
TABLE 357 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 342
TABLE 358 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY USAGE,
2023–2030 (USD MILLION) 343
TABLE 359 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 343
TABLE 360 REST OF GCC COUNTRIES: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 344
TABLE 361 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY END USER,
2023–2030 (USD MILLION) 344
TABLE 362 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY FORMULATION END USER, 2023–2030 (USD MILLION) 345
TABLE 363 REST OF GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 345
TABLE 364 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 346
TABLE 365 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 346
TABLE 366 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET, BY USAGE, 2023–2030 (USD MILLION) 347
TABLE 367 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023–2030 (USD MILLION) 347
TABLE 368 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTOR DEVICES MARKET,
BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 348
TABLE 369 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2023–2030 (USD MILLION) 348
TABLE 370 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET,
BY FORMULATION END USER, 2023–2030 (USD MILLION) 349
TABLE 371 REST OF MIDDLE EAST &AFRICA: WEARABLE INJECTORS MARKET, BY DEVICE END USER, 2023–2030 (USD MILLION) 349
TABLE 372 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN WEARABLE INJECTORS MARKET 351
TABLE 373 GLOBAL WEARABLE INJECTOR DEVICE MANUFACTURERS: DEGREE OF COMPETITION 355
TABLE 374 US MARKET WEARABLE INJECTOR DEVICE MANUFACTURERS: DEGREE OF COMPETITION 356
TABLE 375 GLOBAL WEARABLE INJECTOR FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 358
TABLE 376 US WEARABLE INJECTORS FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 359
TABLE 377 WEARABLE INJECTORS MARKET FOR DEVICES: REGION FOOTPRINT 364
TABLE 378 WEARABLE INJECTORS MARKET FOR DEVICES: PRODUCT TYPE FOOTPRINT 364
TABLE 379 WEARABLE INJECTORS MARKET FOR DEVICES: USAGE FOOTPRINT 365
TABLE 380 WEARABLE INJECTORS MARKET FOR DEVICES: DELIVERY METHOD FOOTPRINT 365
TABLE 381 WEARABLE INJECTORS MARKET FOR DEVICES: TECHNOLOGY TYPE FOOTPRINT 366
TABLE 382 WEARABLE INJECTORS MARKET: DETAILED LIST OF KEY DEVICE STARTUPS/SME PLAYERS 369
TABLE 383 WEARABLE INJECTORS MARKET FOR DEVICES: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 369
TABLE 384 WEARABLE INJECTORS MARKET FOR FORMULATION: REGION FOOTPRINT 372
TABLE 385 WEARABLE INJECTORS MARKET FOR FORMULATION: PRODUCT TYPE FOOTPRINT 373
TABLE 386 WEARABLE INJECTORS MARKET FOR FORMULATION: DELIVERY METHOD FOOTPRINT 373
TABLE 387 WEARABLE INJECTORS MARKET FOR FORMULATION: THERAPEUTIC APPLICATION FOOTPRINT 374
TABLE 388 WEARABLE INJECTORS MARKET FOR FORMULATION: TECHNOLOGY TYPE FOOTPRINT 374
TABLE 389 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022−JULY 2025 377
TABLE 390 WEARABLE INJECTORS MARKET: DEALS, JANUARY 2022−JULY 2025 378
TABLE 391 WEARABLE INJECTORS MARKET: EXPANSIONS, JANUARY 2022–JULY 2025 379
TABLE 392 WEARABLE INJECTOR MARKET: OTHER DEVELOPMENTS,
JANUARY 2022−JULY 2025 380
TABLE 393 INSULET CORPORATION: COMPANY OVERVIEW 381
TABLE 394 INSULET CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 382
TABLE 395 INSULET CORPORATION: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–JULY 2025 383
TABLE 396 INSULET CORPORATION: DEALS, JANUARY 2022−JULY 2025 384
TABLE 397 INSULET CORPORATION: EXPANSIONS, JANUARY 2022−JULY 2025 384
TABLE 398 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 386
TABLE 399 TANDEM DIABETES CARE, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 387
TABLE 400 TANDEM DIABETES CARE, INC.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022−JULY 2025 388
TABLE 401 TANDEM DIABETES CARE, INC.: DEALS, JANUARY 2022−JULY 2025 389
TABLE 402 MEDTRONIC: COMPANY OVERVIEW 391
TABLE 403 MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 392
TABLE 404 MEDTRONIC: PRODUCT LAUNCHES, UPGRADE & APPROVALS,
JANUARY 2022–JULY 2025 393
TABLE 405 MEDTRONIC: DEALS, JANUARY 2022–JULY 2025 393
TABLE 406 BD: COMPANY OVERVIEW 395
TABLE 407 BD: PRODUCTS/SOLUTIONS/SERVICES OFFERED 396
TABLE 408 BD: DEALS, JANUARY 2022–JULY 2025 397
TABLE 409 BD: EXPANSIONS, JANUARY 2022–JULY 2025 397
TABLE 410 BD: OTHER DEVELOPMENTS, JANUARY 2022−JULY 2025 398
TABLE 411 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 399
TABLE 412 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 400
TABLE 413 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,
JANUARY 2022–JULY 2025 401
TABLE 414 GERRESHEIMER AG: COMPANY OVERVIEW 403
TABLE 415 GERRESHEIMER AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 404
TABLE 416 GERRESHEIMER AG: EXPANSIONS, JANUARY 2022–JULY 2025 405
TABLE 417 STEVANATO: COMPANY OVERVIEW 406
TABLE 418 STEVANATO: PRODUCTS/SOLUTIONS/SERVICES OFFERED 407
TABLE 419 STEVANATO: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS,
JANUARY 2022–JULY 2025 408
TABLE 420 STEVANATO: DEALS, JANUARY 2022–JULY 2025 408
TABLE 421 LTS LOHMANN THERAPIE-SYSTEME AG: COMPANY OVERVIEW 409
TABLE 422 LTS LOHMANN THERAPIE-SYSTEME AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 409
TABLE 423 LTS LOHMANN THERAPIE-SYSTEME AG.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022−JULY 2025 410
TABLE 424 LTS LOHMANN THERAPIE-SYSTEME AG.: DEALS, JANUARY 2022−JULY 2025 410
TABLE 425 LTS LOHMANN THERAPIE-SYSTEME AG: EXPANSIONS, JANUARY 2022–JULY 2025 411
TABLE 426 SONCEBOZ: COMPANY OVERVIEW 412
TABLE 427 SONCEBOZ: PRODUCTS/SOLUTIONS/SERVICES OFFERED 412
TABLE 428 NEMERA: COMPANY OVERVIEW 413
TABLE 429 NEMERA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 413
TABLE 430 NEMERA: DEALS, JANUARY 2022−JULY 2025 414
TABLE 431 NEMERA: EXPANSIONS, JANUARY 2022–JULY 2025 414
TABLE 432 MANNKIND CORPORATION: COMPANY OVERVIEW 415
TABLE 433 MANNKIND CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 416
TABLE 434 MANNKIND CORPORATION: DEALS, JANUARY 2022−JULY 2025 416
TABLE 435 ENABLE INJECTIONS: COMPANY OVERVIEW 417
TABLE 436 ENABLE INJECTIONS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 417
TABLE 437 ENABLE INJECTIONS: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–JULY 2025 418
TABLE 438 ENABLE INJECTIONS: DEALS, JANUARY 2022−JULY 2025 418
TABLE 439 ENABLE INJECTIONS: EXPANSIONS, JANUARY 2022–JULY 2025 419
TABLE 440 ENABLE INJECTIONS: OTHER DEVELOPMENTS, JANUARY 2022−JULY 2025 419
TABLE 441 ELCAM MEDICAL: COMPANY OVERVIEW 420
TABLE 442 ELCAM MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED 420
TABLE 443 ELCAM MEDICAL: EXPANSIONS, JANUARY 2022–JULY 2025 421
TABLE 444 DEBIOTECH SA: COMPANY OVERVIEW 422
TABLE 445 MEDTRUM TECHNOLOGIES INC.: COMPANY OVERVIEW 423
TABLE 446 CEQUR SIMPLICITY: COMPANY OVERVIEW 424
TABLE 447 SUBCUJECT APS: COMPANY OVERVIEW 425
TABLE 448 MICROMED CO., LTD: COMPANY OVERVIEW 425
TABLE 449 AMGEN INC.: COMPANY OVERVIEW 426
TABLE 450 AMGEN INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 427
TABLE 451 AMGEN INC.: DEALS, JANUARY 2022−JULY 2025 427
TABLE 452 AMGEN INC.: EXPANSIONS, JANUARY 2022–JULY 2025 428
TABLE 453 ABBVIE INC.: COMPANY OVERVIEW 429
TABLE 454 ABBVIE, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 430
TABLE 455 ABBVIE INC.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS,
JANUARY 2022–JULY 2025 431
TABLE 456 ABBVIE, INC.: EXPANSIONS, JANUARY 2022–JULY 2025 432
TABLE 457 UNITED THERAPEUTICS CORPORATION: COMPANY OVERVIEW 433
TABLE 458 UNITED THERAPEUTICS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 434
TABLE 459 UNITED THERAPEUTICS CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025 434
TABLE 460 APELLIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 435
TABLE 461 APELLIS PHARMACEUTICALS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 436
TABLE 462 APELLIS PHARMACEUTICALS, INC.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022−JUNE 2025 436
TABLE 463 SUPERNUS PHARMACEUTICALS: COMPANY OVERVIEW 437
TABLE 464 SUPERNUS PHARMACEUTICALS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 438
TABLE 465 SUPERNUS PHARMACEUTICALS: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022−JULY 2025 438
TABLE 466 COHERUS BIOSCIENCES, INC.: COMPANY OVERVIEW 439
TABLE 467 COHERUS BIOSCIENCES, INC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 440
TABLE 468 COHERUS BIOSCIENCES, INC.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022−JULY 2025 440
TABLE 469 COHERUS BIOSCIENCES, INC.: OTHER DEVELOPMENTS,
JANUARY 2022−JULY 2025 440
TABLE 470 SCPHARMACEUTICALS, INC.: COMPANY OVERVIEW 441
TABLE 471 SCPHARMACEUTICALS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 442
TABLE 472 SCPHARMACEUTICALS, INC.: PRODUCT LAUNCHES, UPGRADES AND APPROVALS, JANUARY 2022−JULY 2025 442
LIST OF FIGURES
FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION 37
FIGURE 2 WEARABLE INJECTORS MARKET: RESEARCH DESIGN 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE) 48
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 48
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 49
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: INSULET CORPORATION 49
FIGURE 8 SUPPLY-SIDE ANALYSIS OF TOP COMPANIES: WEARABLE INJECTORS MARKET (2024) 50
FIGURE 9 BOTTOM-UP APPROACH 51
FIGURE 10 TOP-DOWN APPROACH 52
FIGURE 11 DEMAND-SIDE ANALYSIS: WEARABLE INJECTORS MARKET 53
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF WEARABLE INJECTORS MARKET (2025–2030) 55
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55
FIGURE 14 MARKET DATA TRIANGULATION 57
FIGURE 15 WEARABLE INJECTORS MARKET, BY PRODUCT, 2025 VS. 2030 60
FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 61
FIGURE 17 WEARABLE INJECTORS MARKET, BY USAGE, 2025 VS. 2030 62
FIGURE 18 WEARABLE INJECTORS MARKET, BY DELIVERY METHOD, 2023 VS. 2030 63
FIGURE 19 WEARABLE INJECTOR DEVICES MARKET, BY THERAPEUTIC APPLICATION,
2025 VS. 2030 64
FIGURE 20 WEARABLE INJECTOR MARKET, BY END USER, 2025 VS. 2030 65
FIGURE 21 REGIONAL SNAPSHOT OF WEARABLE INJECTORS MARKET 66
FIGURE 22 TECHNOLOGICAL ADVANCEMENTS IN WEARABLE INJECTOR DEVICES TO DRIVE MARKET 68
FIGURE 23 ON-BODY WEARABLE INJECTORS LED ASIA PACIFIC WEARABLE INJECTORS MARKET IN 2024 69
FIGURE 24 ASIA PACIFIC TO BE FASTEST-GROWING MARKET DURING FORECAST PERIOD 70
FIGURE 25 INDIA AND CHINA TO WITNESS HIGHEST MARKET GROWTH DURING FORECAST PERIOD 71
FIGURE 26 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 72
FIGURE 27 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
FIGURE 28 BIOPHARMACEUTICAL R&D SPENDING (2020–2026) 78
FIGURE 29 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 89
FIGURE 30 WEARABLE INJECTORS MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014–JULY 2025) 97
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR WEARABLE INJECTOR PATENTS (JANUARY 2014–JULY 2025) 98
FIGURE 32 AVERAGE SELLING PRICE TREND FOR ON-BODY WEARABLE INJECTORS, BY KEY PLAYER, 2024 101
FIGURE 33 AVERAGE SELLING PRICE TREND FOR OFF-BODY WEARABLE INJECTOR, BY KEY PLAYER, 2024 102
FIGURE 34 AVERAGE SELLING PRICE TREND FOR ON-BODY WEARABLE INJECTOR AND OFF-BODY WEARABLE INJECTOR, BY REGION, 2024 102
FIGURE 35 KEY STAKEHOLDERS IN BUYING PROCESS FOR WEARABLE INJECTORS (DEVICES) 106
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR WEARABLE INJECTORS ( FORMULATIONS) 107
FIGURE 37 KEY BUYING CRITERIA FOR TOP THREE END USERS 108
FIGURE 38 AI USE CASES 110
FIGURE 39 WEARABLE INJECTORS MARKET: ECOSYSTEM MAP 112
FIGURE 40 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS 115
FIGURE 41 WEARABLE INJECTORS MARKET: INVESTMENT & FUNDING SCENARIO,
2020–2024 117
FIGURE 42 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR WEARABLE INJECTORS MARKET 122
FIGURE 43 CHINA TO BE FASTEST-GROWING WEARABLE INJECTORS MARKET DURING FORECAST PERIOD 195
FIGURE 44 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT 198
FIGURE 45 ASIA PACIFIC: WEARABLE INJECTORS MARKET SNAPSHOT 255
FIGURE 46 REVENUE ANALYSIS OF WEARABLE INJECTOR DEVICE MANUFACTURERS, 2022−2024 353
FIGURE 47 REVENUE ANALYSIS OF WEARABLE INJECTOR FORMULATION MANUFACTURERS, 2022−2024 354
FIGURE 48 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE INJECTOR DEVICE MANUFACTURERS, 2024 355
FIGURE 49 US MARKET SHARE ANALYSIS OF WEARABLE INJECTOR DEVICE
MANUFACTURERS, 2024 356
FIGURE 50 RANKING OF KEY GLOBAL WEARABLE INJECTOR DEVICE MANUFACTURERS, 2024 357
FIGURE 51 GLOBAL MARKET SHARE ANALYSIS OF WEARABLE INJECTORS FORMULATION MANUFACTURERS, 2024 358
FIGURE 52 US MARKET SHARE ANALYSIS OF WEARABLE INJECTOR FORMULATION MANUFACTURERS, 2024 359
FIGURE 53 RANKING OF KEY GLOBAL WEARABLE INJECTOR FORMULATION
MANUFACTURERS, 2024 360
FIGURE 54 WEARABLE INJECTORS MARKET FOR DEVICES: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 362
FIGURE 55 WEARABLE INJECTOR MARKET FOR DEVICES: COMPANY FOOTPRINT 363
FIGURE 56 WEARABLE INJECTORS MARKET FOR DEVICES: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 368
FIGURE 57 WEARABLE INJECTORS MARKET FOR FORMULATION: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 371
FIGURE 58 WEARABLE INJECTORS MARKET FOR FORMULATION: COMPANY FOOTPRINT 372
FIGURE 59 WEARABLE INJECTORS MARKET: BRAND/PRODUCT COMPARISON 375
FIGURE 60 R&D EXPENDITURE OF KEY PLAYERS IN WEARABLE INJECTORS MARKET, 2022−2024 376
FIGURE 61 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 376
FIGURE 62 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 377
FIGURE 63 INSULET CORPORATION: COMPANY SNAPSHOT (2024) 382
FIGURE 64 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2024) 387
FIGURE 65 MEDTRONIC: COMPANY SNAPSHOT (2024) 392
FIGURE 66 BD: COMPANY SNAPSHOT (2024) 396
FIGURE 67 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024) 400
FIGURE 68 GERRESHEIMER AG: COMPANY SNAPSHOT (2024) 404
FIGURE 69 STEVANATO: COMPANY SNAPSHOT (2024) 407
FIGURE 70 MANNKIND CORPORATION: COMPANY SNAPSHOT (2024) 415
FIGURE 71 AMGEN INC.: COMPANY SNAPSHOT (2024) 426
FIGURE 72 ABBVIE, INC.: COMPANY SNAPSHOT (2024) 430
FIGURE 73 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2024) 434
FIGURE 74 APELLIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 435
FIGURE 75 SUPERNUS PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 437
FIGURE 76 COHERUS BIOSCIENCES, INC: COMPANY SNAPSHOT (2024) 439
FIGURE 77 SCPHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 441
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11